Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1894–1899. doi: 10.1054/bjoc.2001.2159

Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder

J Edwards 1, P Duncan 1, J J Going 2, K M Grigor 3, A D Watters 1, J M S Bartlett 1
PMCID: PMC2364026  PMID: 11747332

Abstract

Approximately 2/3 of patients diagnosed with superficial transitional cell carcinoma of the urinary bladder (TCC) will recur within 2 years. Loss of chromosome 9 and loss of heterozygosity (LOH) at 9q34 in index TCCs identify a subset of patients at high risk of recurrence. This study explores genetic alterations on chromosomes 4, 8, 11 and 17 as predictors of recurrence. A total of 109 carcinomas were investigated at 26 loci. DNA was extracted from microdissected archival normal/tumour tissue and was analysed for loss of heterozygosity (LOH). Fluorescent PCR was performed and genotyping carried out on a Perkin Elmer ABI377 sequencer. LOH of D11S490 or D17S928 was significantly more frequent in index carcinomas of patients who experienced recurrence compared to those with no recurrence (P = 0.004 and 0.019 respectively). These results suggest that loss of these regions is associated with recurrence of TCC. Further investigation is required to identify genes in these regions, which might be responsible for driving recurrence in TCC of the urinary bladder. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: LOH, TCC of the urinary bladder, chromosome 11 and 17

Full Text

The Full Text of this article is available as a PDF (75.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adshead J. M., Kessling A. M., Ogden C. W. Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. Br J Urol. 1998 Oct;82(4):503–512. doi: 10.1046/j.1464-410x.1998.00767.x. [DOI] [PubMed] [Google Scholar]
  2. Ambrosini G., Adida C., Altieri D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997 Aug;3(8):917–921. doi: 10.1038/nm0897-917. [DOI] [PubMed] [Google Scholar]
  3. Bartlett J. M., Watters A. D., Ballantyne S. A., Going J. J., Grigor K. M., Cooke T. G. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br J Cancer. 1998 Jun;77(12):2193–2198. doi: 10.1038/bjc.1998.365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bell S. M., Zuo J., Myers R. M., Knowles M. A. Fluorescence in situ hybridization deletion mapping at 4p16.3 in bladder cancer cell lines refines the localisation of the critical interval to 30 kb. Genes Chromosomes Cancer. 1996 Oct;17(2):108–117. doi: 10.1002/(SICI)1098-2264(199610)17:2<108::AID-GCC6>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  5. Chaturvedi V., Li L., Hodges S., Johnston D., Ro J. Y., Logothetis C., von Eschenbach A. C., Batsakis J. G., Czerniak B. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene. 1997 May 1;14(17):2059–2070. doi: 10.1038/sj.onc.1201044. [DOI] [PubMed] [Google Scholar]
  6. Czerniak B., Chaturvedi V., Li L., Hodges S., Johnston D., Roy J. Y., Luthra R., Logothetis C., Von Eschenbach A. C., Grossman H. B. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999 Feb 4;18(5):1185–1196. doi: 10.1038/sj.onc.1202385. [DOI] [PubMed] [Google Scholar]
  7. Esrig D., Freeman J. A., Stein J. P., Skinner D. G. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol. 1997 Aug;15(3):154–160. [PubMed] [Google Scholar]
  8. Fearon E. R., Feinberg A. P., Hamilton S. H., Vogelstein B. Loss of genes on the short arm of chromosome 11 in bladder cancer. 1985 Nov 28-Dec 4Nature. 318(6044):377–380. doi: 10.1038/318377a0. [DOI] [PubMed] [Google Scholar]
  9. Foulkes W. D., Campbell I. G., Stamp G. W., Trowsdale J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer. 1993 Feb;67(2):268–273. doi: 10.1038/bjc.1993.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Godwin A. K., Vanderveer L., Schultz D. C., Lynch H. T., Altomare D. A., Buetow K. H., Daly M., Getts L. A., Masny A., Rosenblum N. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet. 1994 Oct;55(4):666–677. [PMC free article] [PubMed] [Google Scholar]
  11. Going J. J., Lamb R. F. Practical histological microdissection for PCR analysis. J Pathol. 1996 May;179(1):121–124. doi: 10.1002/(SICI)1096-9896(199605)179:1<121::AID-PATH536>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  12. Hampton G. M., Penny L. A., Baergen R. N., Larson A., Brewer C., Liao S., Busby-Earle R. M., Williams A. W., Steel C. M., Bird C. C. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6953–6957. doi: 10.1073/pnas.91.15.6953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Iizuka M., Sugiyama Y., Shiraishi M., Jones C., Sekiya T. Allelic losses in human chromosome 11 in lung cancers. Genes Chromosomes Cancer. 1995 May;13(1):40–46. doi: 10.1002/gcc.2870130107. [DOI] [PubMed] [Google Scholar]
  14. Jacobs I. J., Smith S. A., Wiseman R. W., Futreal P. A., Harrington T., Osborne R. J., Leech V., Molyneux A., Berchuck A., Ponder B. A. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res. 1993 Mar 15;53(6):1218–1221. [PubMed] [Google Scholar]
  15. Kalikin L. M., Frank T. S., Svoboda-Newman S. M., Wetzel J. C., Cooney K. A., Petty E. M. A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors. Oncogene. 1997 Apr 24;14(16):1991–1994. doi: 10.1038/sj.onc.1201013. [DOI] [PubMed] [Google Scholar]
  16. Kalikin L. M., Qu X., Frank T. S., Caduff R. F., Svoboda S. M., Law D. J., Petty E. M. Detailed deletion analysis of sporadic breast tumors defines an interstitial region of allelic loss on 17q25. Genes Chromosomes Cancer. 1996 Sep;17(1):64–68. doi: 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  17. Knowles M. A. Identification of novel bladder tumour suppressor genes. Electrophoresis. 1999 Feb;20(2):269–279. doi: 10.1002/(SICI)1522-2683(19990201)20:2<269::AID-ELPS269>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  18. Knowles M. A. Molecular genetics of bladder cancer. Br J Urol. 1995 Jun;75 (Suppl 1):57–66. [PubMed] [Google Scholar]
  19. Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C., Altieri D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998 Dec 10;396(6711):580–584. doi: 10.1038/25141. [DOI] [PubMed] [Google Scholar]
  20. Lupher M. L., Jr, Rao N., Lill N. L., Andoniou C. E., Miyake S., Clark E. A., Druker B., Band H. Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J Biol Chem. 1998 Dec 25;273(52):35273–35281. doi: 10.1074/jbc.273.52.35273. [DOI] [PubMed] [Google Scholar]
  21. Monaco C., Negrini M., Sozzi G., Veronese M. L., Vorechovsky I., Godwin A. K., Croce C. M. Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. Genomics. 1997 Dec 1;46(2):217–222. doi: 10.1006/geno.1997.5036. [DOI] [PubMed] [Google Scholar]
  22. Murakami Y., Nobukuni T., Tamura K., Maruyama T., Sekiya T., Arai Y., Gomyou H., Tanigami A., Ohki M., Cabin D. Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8153–8158. doi: 10.1073/pnas.95.14.8153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Niederacher D., Picard F., van Roeyen C., An H. X., Bender H. G., Beckmann M. W. Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis. Genes Chromosomes Cancer. 1997 Mar;18(3):181–192. doi: 10.1002/(sici)1098-2264(199703)18:3<181::aid-gcc5>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  24. Nishiyama H., Hornigold N., Davies A. M., Knowles M. A. A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33. Genomics. 1999 Aug 1;59(3):335–338. doi: 10.1006/geno.1999.5891. [DOI] [PubMed] [Google Scholar]
  25. O'Neill K. L., McKelvey V. J., Hoper M., Monteverde H., Odling-Smee G. W., Logan H., Abram W. P., McKenna P. G. Breast tumour thymidine kinase levels and disease recurrence. Med Lab Sci. 1992 Dec;49(4):244–247. [PubMed] [Google Scholar]
  26. Ohgaki K., Iida A., Ogawa O., Kubota Y., Akimoto M., Emi M. Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a 1-Mb interval on 8p22. Genes Chromosomes Cancer. 1999 May;25(1):1–5. doi: 10.1002/(sici)1098-2264(199905)25:1<1::aid-gcc1>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  27. Petty E. M., Kalikin L. M., Orringer M. B., Beer D. G. Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis. Mol Carcinog. 1998 Aug;22(4):222–228. doi: 10.1002/(sici)1098-2744(199808)22:4<222::aid-mc3>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  28. Petty E. M., Miller D. E., Grant A. L., Collins E. E., Glover T. W., Law D. J. FISH localization of the soluble thymidine kinase gene (TK1) to human 17q25, a region of chromosomal loss in sporadic breast tumors. Cytogenet Cell Genet. 1996;72(4):319–321. doi: 10.1159/000134213. [DOI] [PubMed] [Google Scholar]
  29. Plummer S. J., Adams L., Simmons J. A., Casey G. Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25. Oncogene. 1997 May 15;14(19):2339–2345. doi: 10.1038/sj.onc.1201073. [DOI] [PubMed] [Google Scholar]
  30. Richter J., Jiang F., Görög J. P., Sartorius G., Egenter C., Gasser T. C., Moch H., Mihatsch M. J., Sauter G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997 Jul 15;57(14):2860–2864. [PubMed] [Google Scholar]
  31. Sauter G., Carroll P., Moch H., Kallioniemi A., Kerschmann R., Narayan P., Mihatsch M. J., Waldman F. M. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol. 1995 May;146(5):1131–1139. [PMC free article] [PubMed] [Google Scholar]
  32. Shaw M. E., Knowles M. A. Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes Cancer. 1995 May;13(1):1–8. doi: 10.1002/gcc.2870130102. [DOI] [PubMed] [Google Scholar]
  33. Sidransky D., Von Eschenbach A., Tsai Y. C., Jones P., Summerhayes I., Marshall F., Paul M., Green P., Hamilton S. R., Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991 May 3;252(5006):706–709. doi: 10.1126/science.2024123. [DOI] [PubMed] [Google Scholar]
  34. Simon R., Bürger H., Brinkschmidt C., Böcker W., Hertle L., Terpe H. J. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol. 1998 Aug;185(4):345–351. doi: 10.1002/(SICI)1096-9896(199808)185:4<345::AID-PATH109>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  35. Spruck C. H., 3rd, Ohneseit P. F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y. C., Lerner S. P., Schmütte C., Yang A. S., Cote R. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994 Feb 1;54(3):784–788. [PubMed] [Google Scholar]
  36. Theile M., Hartmann S., Scherthan H., Arnold W., Deppert W., Frege R., Glaab F., Haensch W., Scherneck S. Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. Oncogene. 1995 Feb 2;10(3):439–447. [PubMed] [Google Scholar]
  37. Tsutsumi M., Sugano K., Yamaguchi K., Kakizoe T., Akaza H. Correlation of allelic loss of the P53 gene and tumor grade, stage, and malignant progression in bladder cancer. Int J Urol. 1997 Jan;4(1):74–78. doi: 10.1111/j.1442-2042.1997.tb00144.x. [DOI] [PubMed] [Google Scholar]
  38. Voorter C. E., Ummelen M. I., Ramaekers F. S., Hopman A. H. Loss of chromosome 11 and 11 p/q imbalances in bladder cancer detected by fluorescence in situ hybridization. Int J Cancer. 1996 Jan 26;65(3):301–307. doi: 10.1002/(SICI)1097-0215(19960126)65:3<301::AID-IJC4>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  39. Wagner U., Bubendorf L., Gasser T. C., Moch H., Görög J. P., Richter J., Mihatsch M. J., Waldman F. M., Sauter G. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol. 1997 Sep;151(3):753–759. [PMC free article] [PubMed] [Google Scholar]
  40. Wagner U., Süess K., Luginbühl T., Schmid U., Ackermann D., Zellweger T., Maurer R., Alund G., Knönagel H., Rist M. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol. 1999 May;188(1):44–50. doi: 10.1002/(SICI)1096-9896(199905)188:1<44::AID-PATH320>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  41. Watters A. D., Ballantyne S. A., Going J. J., Grigor K. M., Bartlett J. M. Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. BJU Int. 2000 Jan;85(1):42–47. doi: 10.1046/j.1464-410x.2000.00326.x. [DOI] [PubMed] [Google Scholar]
  42. van der Meijden A. P. Bladder cancer. BMJ. 1998 Nov 14;317(7169):1366–1369. doi: 10.1136/bmj.317.7169.1366. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES